1. Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double- blind placebo-controlled trial 
Patricia van Velzen, MD, Gerben ter Riet, MD, Paul Bresser, MD, Jeroen J Baars, MD, Bob T J van den Berg, MD, Jan W K van den Berg, MD, Paul Brinkman, Jennece W F Dagelet, Johannes M A Daniels, MD, Dewi R G L Groeneveld-Tjiong, MD, René E Jonkers, MD, Coen van Kan, MD, Frans H Krouwels, MD, Karin Pool, MD, Arjan Rudolphus, MD, Prof Peter J Sterk, MD, Prof Jan M Prins, MD 
The Lancet Respiratory Medicine 
Volume 5, Issue 6, Pages (June 2017)
DOI: /S (17)
Copyright © 2017 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The Lancet Respiratory Medicine 2017 5, DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions

3. Figure 2 Proportion of patients free of a second exacerbation
HR=hazard ratio.
The Lancet Respiratory Medicine 2017 5, DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions

4. Figure 3 Subgroup analyses for patients who had a second exacerbation
We calculated HRs with Cox regression with terms for treatment. HR=hazard ratio. GOLD=Global Initiative of Chronic Obstructive Lung Disease. GP=general practitioner.
The Lancet Respiratory Medicine 2017 5, DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions